These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 14517717)
1. A rapid multiparameter approach to study factors that regulate osteoclastogenesis: demonstration of the combinatorial dominant effects of TNF-alpha and TGF-ss in RANKL-mediated osteoclastogenesis. Huang W; Drissi MH; O'Keefe RJ; Schwarz EM Calcif Tissue Int; 2003 Dec; 73(6):584-93. PubMed ID: 14517717 [TBL] [Abstract][Full Text] [Related]
2. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions. Quinn JM; Itoh K; Udagawa N; Hausler K; Yasuda H; Shima N; Mizuno A; Higashio K; Takahashi N; Suda T; Martin TJ; Gillespie MT J Bone Miner Res; 2001 Oct; 16(10):1787-94. PubMed ID: 11585342 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population. Nagata N; Kitaura H; Yoshida N; Nakayama K Bone; 2003 Oct; 33(4):721-32. PubMed ID: 14555278 [TBL] [Abstract][Full Text] [Related]
4. The immunosuppressant rapamycin, alone or with transforming growth factor-beta, enhances osteoclast differentiation of RAW264.7 monocyte-macrophage cells in the presence of RANK-ligand. Shui C; Riggs BL; Khosla S Calcif Tissue Int; 2002 Nov; 71(5):437-46. PubMed ID: 12202955 [TBL] [Abstract][Full Text] [Related]
5. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse. Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637 [TBL] [Abstract][Full Text] [Related]
6. Interleukin-4 directly inhibits tumor necrosis factor-alpha-mediated osteoclast formation in mouse bone marrow macrophages. Kitaura H; Nagata N; Fujimura Y; Hotokezaka H; Tatamiya M; Nakao N; Yoshida N; Nakayama K Immunol Lett; 2003 Sep; 88(3):193-8. PubMed ID: 12941478 [TBL] [Abstract][Full Text] [Related]
7. CpG oligonucleotides: novel regulators of osteoclast differentiation. Zou W; Schwartz H; Endres S; Hartmann G; Bar-Shavit Z FASEB J; 2002 Mar; 16(3):274-82. PubMed ID: 11874977 [TBL] [Abstract][Full Text] [Related]
8. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. Lam J; Takeshita S; Barker JE; Kanagawa O; Ross FP; Teitelbaum SL J Clin Invest; 2000 Dec; 106(12):1481-8. PubMed ID: 11120755 [TBL] [Abstract][Full Text] [Related]
9. Interleukin (IL)-12 mediates the anti-osteoclastogenic activity of CpG-oligodeoxynucleotides. Amcheslavsky A; Bar-Shavit Z J Cell Physiol; 2006 Apr; 207(1):244-50. PubMed ID: 16402377 [TBL] [Abstract][Full Text] [Related]
10. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. Michigami T; Ihara-Watanabe M; Yamazaki M; Ozono K Cancer Res; 2001 Feb; 61(4):1637-44. PubMed ID: 11245477 [TBL] [Abstract][Full Text] [Related]
11. RANKL coordinates cell cycle withdrawal and differentiation in osteoclasts through the cyclin-dependent kinase inhibitors p27KIP1 and p21CIP1. Sankar U; Patel K; Rosol TJ; Ostrowski MC J Bone Miner Res; 2004 Aug; 19(8):1339-48. PubMed ID: 15231022 [TBL] [Abstract][Full Text] [Related]
12. T-cells mediate an inhibitory effect of interleukin-4 on osteoclastogenesis. Mirosavljevic D; Quinn JM; Elliott J; Horwood NJ; Martin TJ; Gillespie MT J Bone Miner Res; 2003 Jun; 18(6):984-93. PubMed ID: 12817750 [TBL] [Abstract][Full Text] [Related]
13. Dual modulation of osteoclast differentiation by lipopolysaccharide. Zou W; Bar-Shavit Z J Bone Miner Res; 2002 Jul; 17(7):1211-8. PubMed ID: 12096834 [TBL] [Abstract][Full Text] [Related]
14. RANKL is an essential cytokine mediator of polymethylmethacrylate particle-induced osteoclastogenesis. Clohisy JC; Frazier E; Hirayama T; Abu-Amer Y J Orthop Res; 2003 Mar; 21(2):202-12. PubMed ID: 12568950 [TBL] [Abstract][Full Text] [Related]
15. Dietary n-3 fatty acids decrease osteoclastogenesis and loss of bone mass in ovariectomized mice. Sun D; Krishnan A; Zaman K; Lawrence R; Bhattacharya A; Fernandes G J Bone Miner Res; 2003 Jul; 18(7):1206-16. PubMed ID: 12854830 [TBL] [Abstract][Full Text] [Related]
16. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption. Michael H; Härkönen PL; Väänänen HK; Hentunen TA J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275 [TBL] [Abstract][Full Text] [Related]
17. Interleukin-7 is a direct inhibitor of in vitro osteoclastogenesis. Lee SK; Kalinowski JF; Jastrzebski SL; Puddington L; Lorenzo JA Endocrinology; 2003 Aug; 144(8):3524-31. PubMed ID: 12865334 [TBL] [Abstract][Full Text] [Related]
18. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand. Lee CK; Lee EY; Chung SM; Mun SH; Yoo B; Moon HB Arthritis Rheum; 2004 Dec; 50(12):3831-43. PubMed ID: 15593184 [TBL] [Abstract][Full Text] [Related]
19. Prostaglandin E(2) is a main mediator in receptor activator of nuclear factor-kappaB ligand-dependent osteoclastogenesis induced by Porphyromonas gingivalis, Treponema denticola, and Treponema socranskii. Choi BK; Moon SY; Cha JH; Kim KW; Yoo YJ J Periodontol; 2005 May; 76(5):813-20. PubMed ID: 15898943 [TBL] [Abstract][Full Text] [Related]
20. Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha. Dai SM; Nishioka K; Yudoh K Ann Rheum Dis; 2004 Nov; 63(11):1379-86. PubMed ID: 15479886 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]